Form 4: Edwards Lifesciences Director Feinberg Receives Stock Grant

David T. Feinberg, a director at Edwards Lifesciences, acquired 3,528 shares of common stock through a restricted stock unit grant.

Summary

• On May 9, 2025, David T. Feinberg, a director of Edwards Lifesciences Corp, acquired 3,528 shares of common stock.
• The acquisition was a grant of restricted stock units under the company's 2020 Nonemployee Directors Stock Incentive Program.
• These restricted stock units will vest 100% after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
• Following the transaction, Feinberg directly owns 5,836 shares of Edwards Lifesciences common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine stock grant to a director, which is generally viewed neutrally to positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The restricted stock units will vest 100% after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

Industry Context

Stock grants to directors are a common practice to incentivize and align their interests with the company's long-term performance.

Stakeholder Impact

• The stock grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates

Keywords

Edwards Lifesciences, Director, Feinberg, Stock Grant, Restricted Stock Units, Beneficial Ownership, Form 4